Europe Gastrointestinal Drugs Companies
General overview of the pharmaceutical industry in Europe, the Middle East, and Africa (EMEA) with a focus on gastrointestinal drugs.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Europe, the Middle East and Africa Gastrointestinal Drugs Companies Update
October 2023: Self-insured companies and plan sponsors around the country planned to take advantage of Parsley Health's gastrointestinal program, a digital health initiative aimed at reducing expenses in patients with complicated and chronic diseases through the use of root cause medicine. Employers may save money with this innovative benefit, which targets the roughly 50% of women and 37% of men who have at least one gastrointestinal issue. For both sexes combined, the direct cost of treating gastrointestinal conditions is over $135 billion per year, placing it in the top five expense categories for businesses. Autoimmunity, hormone balance, and mental health are all impacted by gastrointestinal disorders. Their most recent poll of working women confirmed that this is a major reason why women miss time in the office. Intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), Crohn's disease (CD), and other gastrointestinal disorders are all covered extensively in the curriculum.
July 2022: The launch of the blockbuster biologic medication Vedolizumab in India was announced by Takeda India, a division of the Japanese pharmaceutical firm Takeda Pharmaceutical Company. The drug is part of the Gastrointestinal (GI) portfolio. Haematology, Genetic Diseases, and Immunology is Takeda's first therapeutic area in India, whereas GI is their second. For the treatment of chronic inflammatory bowel illnesses (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD), vedolizumab will be offered in India under the brand name Kynteles. Kynteles has demonstrated positive safety and effectiveness outcomes in the treatment of individuals with moderate to severe inflammatory bowel disease (IBD), according to the business. The business did not reveal the pricing, but they did say it will be priced with the Indian market's affordability and accessibility in mind.List of Europe, the Middle East and Africa Gastrointestinal Drugs Key companies in the market
- AstraZeneca Plc.(UK)
- Johnson & Johnson (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Valeant Pharmaceuticals Inc. (US)
- Sanofi Ltd. (France)
- Valeant (US)
- Abbott Laboratories(US)
- Allergan Plc (US)
- Bayer AG (Germany)
- Janssen Biotech Inc. (US)
- AbbVie Inc. (US)
- Janssen Biotech (US)
- GlaxoSmithKline Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)
Europe Gastrointestinal Drugs Market Highlights:
Europe, Middle East and Africa Gastrointestinal Drugs Market Scenario:
Gastrointestinal (GI) drug market is projected to reach USD 6,000.27 Million by 2030 at 6.8% CAGR during the forecast period 2022-2030. Gastroesophageal reflux is the most common disease and is responsible for generating a good market. The major driving factor for this market are increasing prevalence of many gastrointestinal disease. In addition to this, technological advances, infrastructure development increasing investment in research activity and increasing awareness about the availability of treatment are responsible for providing fuel for the growth of the market. While incorrect self-diagnosis and availability of many misbranded drug are the major restraining factor for the growth of market. Study Objectives Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report
- Market Analysis of Europe, Middle East and Africa Gastrointestinal Drugs Market, with region assessment and competitive analysis.
- Detail market identification with its drivers and restrain of the market.
- To provide thorough understanding of various segment and sub segments of the market.
- Analysis of market on the basis of different factors like price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to their main geographies and their countries
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Europe, Middle East and Africa Gastrointestinal Drugs Market.
- Information about the key companies that may influence this market in this region.
Figure 1- Europe, Middle East and Africa Gastrointestinal Drugs Market, by Disease type 
Key Players for Europe, Middle East and Africa Gastrointestinal Drugs market AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Segmentation Europe, Middle East and Africa gastrointestinal drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. Acid Neutralizers are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and others. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease type they are segmented into Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. By End User Hospital Pharmacies, Retail Pharmacies and Other
Research Methodology
Regional Analysis Europe is the second major contributor in the GI drug market globally. Total Europe and Middle East and Africa GI drug market in 2016 was approximately USD$ 15 million. Germany and France are the major contributor of the market this is due to a huge number of patient suffering from different GI problems. About 9.2% of total population in France is suffering from acute or chronic GI problems. This is the major factor responsible for the growth of market. Due to saturation of market in this region the market is growing at a steady CAGR of 4.5 % during 2017-2023.
The report for Europe, Middle East and Africa Gastrointestinal Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
 Intended Audience
- Manufacturing industries.
- Pharmaceutical industry.
- Biotechnology Companies
- Research and Development (R&D) CompaniesÂ
Europe Gastrointestinal Drugs Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
